To further interrogate the underlying biology of NR4A2/hA1R engineered CAR T cells we performed bulk ATAC-seq of NR4A2/hA1R CAR T cells after OVCAR-3 tumor stimulation which demonstrated clear epigenetic changes in NR4A2/A1R engineered CAR T cells that were only apparent following activation (Fig. 3J, K). The gene discussed is NR4A2; the disease is neoplasm.